-
1 Comment
Granules India Limited is currently in a long term downtrend where the price is trading 2.1% below its 200 day moving average.
From a valuation standpoint, the stock is 45.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.6.
Granules India Limited's total revenue rose by 20.0% to $8B since the same quarter in the previous year.
Its net income has increased by 129.3% to $1B since the same quarter in the previous year.
Finally, its free cash flow fell by 13.5% to $2B since the same quarter in the previous year.
Based on the above factors, Granules India Limited gets an overall score of 3/5.
Sector | Healthcare |
---|---|
Industry | Drug Manufacturers - Specialty & Generic |
Exchange | NSE |
CurrencyCode | INR |
ISIN | INE101D01020 |
Market Cap | 111B |
---|---|
Dividend Yield | 0.0% |
PE Ratio | 22.23 |
Beta | -0.13 |
Target Price | 585 |
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationally. It offers paracetamol, metformin, guaifenesin, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions. In addition, it provides development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives. The company offers its products in various therapeutic categories, including antiretroviral, anti-depressant, antihistamine, anti-diabetic, anti-cancer, multiple sclerosis, anti-thrombocytopenia, anti-ulcer, anti-convulsant, mucolytic/expectorant, anti-hypertensive, muscle relaxant, NSAIDs, anti-fibrotic, and anti-microbial, as well as anti-arrhythmic, CNS stimulant, anti-diarrheal, antihypertensive, uterine stimulant, chelating agent, mineral supplements, CNS depressant, PDE inhibitor, antispasmodic, and anti-viral. Granules India Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for GRANULES.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025